NBE-Therapeutics is developing best-in-class cancer therapies to increase survival and improve quality of life for cancer patients worldwide. The company’s next-generation immune-stimulatory therapies are based on a proprietary, highly differentiated Antibody-Drug Conjugate (ADC) platform. This best-in-class ADC platform creates highly potent and safe immune-stimulatory ADCs ("iADCs™") with an anthracycline payload, not only directly targeting tumor cells, but also inducing a long-lasting immunological anti-tumor effect. The company’s lead asset, NBE-002, an anti-ROR1 ADC, is due to start first-in-human clinical trials in three US centers by the end of 2020, focusing on triple negative breast cancer, but also other solid cancer indications which express ROR1.

NBE-Therapeutics is a privately owned biotech company based in Basel, financed by Germany’s Boehringer Ingelheim Venture Fund, the Czech Republic’s PPF Group and Denmark’s Novo Holdings as international institutional investors, and by Swiss, German, and Dutch private investors. The company has raised over USD 65m, including a USD 22m Series C (2020), two USD 20m Series B rounds (2016 & 2018), a USD 3m Series A (2015), and over USD 4m from several non-dilutive grants from organizations including the Swiss Commission for Technology & Innovation, the European Commission, and Systems-X.

Biotechnology

NBE Therapeutics

NBE Therapeutics' headquarters in Basel, Switzerland

Gerd Munzert

Florian Durante

Carl Deutsch, PhD, MBA

Cornelia Baumgartner- Diolaiuti

Ulrike Fiedler

Giuliano Bellapadrona

Marco Meier

Thomas Winkler

Anthony W. Tolcher

Jaap Verweij

Alfred Zippelius

The Research and Development Team at NBE Therapeutics is dedicated to advancing the company's innovative ADC platform and developing cutting-edge cancer therapies. This team conducts rigorous preclinical research, formulates and tests novel iADCs™, and collaborates closely with clinical teams to ensure a smooth transition to human trials. Their work is vital in identifying new therapeutic targets and optimizing existing assets to enhance the efficacy and safety of cancer treatments, ultimately aiming to improve outcomes for patients with difficult-to-treat tumors.

Research and Development Team

The Leadership Team at NBE Therapeutics is responsible for setting the strategic direction and overseeing the overall operations of the company. Comprising key executives such as the CEO, Chief Clinical Officer, and Chief Scientific Officer, this team drives innovation in cancer therapy development, ensuring alignment between clinical, scientific, and business objectives while fostering collaborations with investors and regulatory bodies to advance the company's pipeline of next-generation immune-stimulatory therapies.

Leadership Team

The Clinical Operations Team at NBE Therapeutics is responsible for overseeing the planning, execution, and management of clinical trials for the company's innovative cancer therapies. They ensure adherence to regulatory standards, coordinate with clinical sites, and manage the logistics of trial materials, while also leading efforts in trial design and strategy. This team plays a critical role in advancing the company's lead asset, NBE-002, through the clinical development process to deliver breakthrough treatments to patients.

NBE Therapeutics

Org chart

Board & advisors

Teams

Research and Development Team

Leadership Team

Clinical Operations Team

Offices

NBE Therapeutics

Org chart

Board & advisors

Teams

Research and Development Team

Leadership Team

Clinical Operations Team

Offices

Related companies